OBSRV Stock Overview Engages in developing and commercializing medical technology products for patients, healthcare professionals, and hospitals in Norway, Sweden, the United States, and rest of European countries. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Observe Medical ASA Competitors Price History & Performance
Summary of share price highs, lows and changes for Observe Medical Historical stock prices Current Share Price NOK 4.00 52 Week High NOK 8.70 52 Week Low NOK 3.52 Beta 0.32 1 Month Change -27.27% 3 Month Change -21.57% 1 Year Change -22.93% 3 Year Change -95.91% 5 Year Change -97.00% Change since IPO -95.56%
Recent News & Updates
Observe Medical Asa Announces Resignation of Kathrine Elisabeth Gamborg Andreassen as Board of Directors, Effective 5 February 2025 Feb 05
New major risk - Financial data availability Jan 13
New major risk - Shareholder dilution Jan 02
Observe Medical ASA, Annual General Meeting, May 28, 2025 Dec 21 Observe Medical ASA to Report Q4, 2024 Results on Mar 18, 2025 Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 0.921573 million. Dec 05
See more updates
Observe Medical Asa Announces Resignation of Kathrine Elisabeth Gamborg Andreassen as Board of Directors, Effective 5 February 2025 Feb 05
New major risk - Financial data availability Jan 13
New major risk - Shareholder dilution Jan 02
Observe Medical ASA, Annual General Meeting, May 28, 2025 Dec 21 Observe Medical ASA to Report Q4, 2024 Results on Mar 18, 2025 Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 0.921573 million. Dec 05
New major risk - Share price stability Nov 20
First half 2024 earnings released: kr0.12 loss per share (vs kr0.66 loss in 1H 2023) Sep 01
Observe Medical ASA Appoints Jørgen Mann as Permanent CEO Aug 13
Is Observe Medical (OB:OBSRV) Using Too Much Debt? Jun 27 Observe Medical Asa Announces CFO Changes Mar 22
Full year 2023 earnings released: kr1.05 loss per share (vs kr1.08 loss in FY 2022) Mar 14
New minor risk - Financial data availability Mar 12
New major risk - Shareholder dilution Dec 24
Chief Financial Officer exercised options to buy kr149k worth of stock. Dec 21 Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 35.670322 million. Dec 14
Observe Medical ASA to Report First Half, 2024 Results on Aug 30, 2024
Observe Medical ASA (OB:OBSRV) signed a letter of intent to acquire UnoMeter portfolio of Nordic distributor Vingmed from Vingmed AS. Nov 15 Observe Medical ASA has filed a Follow-on Equity Offering in the amount of NOK 55 million. Nov 02
Observe Medical ASA announced that it has received NOK 7.25 million in funding Sep 13
Second quarter 2023 earnings released: kr0.33 loss per share (vs kr0.15 loss in 2Q 2022) Aug 27
New major risk - Share price stability Jul 05
Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021) Feb 19
Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer Jan 11
Observe Medical ASA to Report Fiscal Year 2022 Final Results on Apr 28, 2023 Jan 04 Observe Medical ASA to Report First Half, 2023 Results on Aug 25, 2023
No independent directors Nov 16
Third quarter 2022 earnings released: kr0.28 loss per share (vs kr0.43 loss in 3Q 2021) Nov 05
Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt Sep 23
Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022 Sep 10
Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.068 profit in 2Q 2021) Aug 25
Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way? Jun 07
Observe Medical ASA Announces Executive Appointments Jun 04
First quarter 2022 earnings released: kr0.46 loss per share (vs kr0.25 loss in 1Q 2021) Jun 04
Observe Medical ASA to Report Q1, 2022 Results on Jun 03, 2022 May 12
No independent directors Apr 27
Full year 2021 earnings released: kr1.34 loss per share (vs kr2.22 loss in FY 2020) Mar 30
Observe Medical ASA Announces Executive Changes Mar 29 Observe Medical ASA (OB:OBSRV) completed the acquisition of Biim Ultrasound AS. Mar 10
Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt Feb 08
Observe Medical ASA to Report Q4, 2022 Results on Mar 29, 2022 Feb 01
We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt Sep 11
First quarter 2021 earnings released May 13
Nya Karolinska Sjukhuset Initiates New Studies to Broaden the Clinical Scope of Use for Sippi May 07
Observe Medical Asa Announces an Order to Deliver Newly Introduced Blood & Fluid Warmer System, Including Disposable Supplies, to Two University Hospitals and One Regional Hospital in Nordic Market Mar 09
Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt Mar 02
Full year 2020 earnings released: kr1.88 loss per share (vs kr1.36 loss in FY 2019) Feb 25
Observe Medical ASA announces Nya Karolinska Sjukhuset in Sweden Resumes the Implementation of Sippi® in Clinical Use At Cardiothoracic ICU Unit Feb 23
New 90-day high: kr29.80 Feb 22
Observe Medical Asa Announces Hospital in Northern Italy Has Equipped the Icu Department with Sippi® Systems in Clinical Use Feb 14
Observe Medical ASA Announces Collaborations with the Norwegian Medtech Agency and Yallow Life Science AS Feb 05
New 90-day high: kr16.00 Feb 04
Observe Medical Receives Significant Order for Medical Consumables from A Hospital Region in the Nordic Market Jan 31
Observe Medical ASA Announces Doctoral Dissertation Further Demonstrates Clinical Benefits of Sippi® Jan 15
New 90-day high: kr14.70 Jan 13 Observe Medical ASA Appoints Anders Nachtweij as New Head of Sales
New 90-day low: kr11.40 Dec 08
New 90-day low: kr11.90 Nov 16
Observe Medical ASA (OB:OBSERV) completed the acquisition of Sylak AB from ABIGO Medical AB. Oct 31
New 90-day low: kr12.00 Oct 29
Observe Medical ASA (OB:OBSERV) signed a non-binding term sheet Sylak AB from ABIGO Medical AB for SEK 6 million. Oct 18
New 90-day low: kr13.20 Sep 29
Earnings released Aug 22 Observe Medical ASA to Report Q1, 2021 Results on May 12, 2021
Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 44.999999 million. Jul 08 Shareholder Returns OBSRV NO Medical Equipment NO Market 7D -7.0% -2.1% 0.5% 1Y -22.9% 12.0% 9.0%
See full shareholder returns
Return vs Market: OBSRV underperformed the Norwegian Market which returned 9% over the past year.
Price Volatility Is OBSRV's price volatile compared to industry and market? OBSRV volatility OBSRV Average Weekly Movement 16.4% Medical Equipment Industry Average Movement 6.4% Market Average Movement 5.2% 10% most volatile stocks in NO Market 12.9% 10% least volatile stocks in NO Market 2.6%
Stable Share Price: OBSRV's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: OBSRV's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company Observe Medical ASA engages in developing and commercializing medical technology products for patients, healthcare professionals, and hospitals in Norway, Sweden, the United States, and rest of European countries. It offers Sippi, a digital and automated urine measurement system for urine monitoring and biofilm control; and Biim, a wireless pocketable ultrasound device for display of the ultrasound image and video for nurses and medical staff. The company also offers Unometer, Safeti Plus, Unometer 500, UnoMeter, and AbdoPressure products used for drainage, collection, and measurement of urine output from patients, as well as provides medtech devices and disposables within urine measurement, anesthesiology/ICUs, and wound care products.
Show more Observe Medical ASA Fundamentals Summary How do Observe Medical's earnings and revenue compare to its market cap? OBSRV fundamental statistics Market cap NOK 77.03m Earnings (TTM ) -NOK 47.68m Revenue (TTM ) NOK 29.18m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) OBSRV income statement (TTM ) Revenue NOK 29.18m Cost of Revenue NOK 19.18m Gross Profit NOK 10.00m Other Expenses NOK 57.68m Earnings -NOK 47.68m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 18, 2025
Earnings per share (EPS) -2.48 Gross Margin 34.26% Net Profit Margin -163.41% Debt/Equity Ratio 52.1%
How did OBSRV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/21 23:13 End of Day Share Price 2025/02/21 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Observe Medical ASA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
